Market Cap 287.24M
Revenue (ttm) 0.00
Net Income (ttm) -80.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,012,500
Avg Vol 2,968,538
Day's Range N/A - N/A
Shares Out 82.78M
Stochastic %K 52%
Beta 1.05
Analysts Strong Sell
Price Target $16.70

Company Profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Industry: Biotechnology
Sector: Healthcare
Phone: 844 511 9056
Address:
Three Bala Plaza East, Suite 506, Bala Cynwyd, United States
Quantumup
Quantumup Dec. 1 at 1:03 PM
Cantor reitd $LXEO OW/$19 after survey $LRMR $BIIB Cantor Overall sentiment was very positive on LXEO, with investors expressing that the value of FA cardiomyopathy (AAVrh10- based gene therapy, LX2006) alone is undervalued (although consensus is that LXEO has a good case to support a broad FA label). Beyond this, there is some excitement around PKP2-ACM, especially as LXEO could differentiate on safety, and it represents a significant market opportunity. That said, to an extent, we still think it is under the radar and not all investors we we have spoken with appreciate the level of data LXEO has generated to date and what will be coming in January. Thus, upcoming PKP2-ACM data could put LXEO on more investor radars. Some investors are still questioning the regulatory path for gene therapy overall, and we'd highlight it's critical to understand key differences between companies and approaches. In particular, we emphasize LXEO has established its pivotal plans prior to starting this study.
0 · Reply
GoLoco511
GoLoco511 Nov. 21 at 7:42 PM
$LRMR got into this play as a fun lotto after seeing massive option volume. I believe it was a 2.5c/5c debit spread that expires today. OI still remains, there had been times that the 2.5c was quite profitable but OI never changed. Wondering if we see a big roll, or maybe it was a hedge. It’s safely ITM so it’s not expiring worthless, but I do believe it’s a bit under the breakeven from when it was opened. Have been accumulating some commons though (still don’t know shit about the company) and sold my 2.5c. Going to reenter some longer dated calls though
0 · Reply
XRaYGuru
XRaYGuru Nov. 14 at 2:52 AM
$LRMR why this is 15% in after hours?
0 · Reply
dixiebull
dixiebull Nov. 8 at 10:55 AM
$RCAT nice move from 7.75 to 9.47, see if 9.15 can hold for a move to 10 $ONDS strong Friday from 4.83 to 6.89. If 6.25 can hold this can continue to 7 and 7.50 $LRMR gets a $16.71 price target from analysts. I want 3.15 to hold on a dip to break 3.50 for 4 and 4.25 $MTC almost got 3.50 and holding 2.50 now, risky stock but if 2.50 holds it can go back to 3 and 3.50 if they decide to pump it $AREC not a fast mover but went from 3.31 to 4.16. See if 4 can hold for a move to 4.50, maybe 4.85/5 The first week of Nov was awful so we will see how this week goes. Decent earnings coming this week. We will find something.
0 · Reply
Ab3000
Ab3000 Nov. 6 at 6:49 PM
$LRMR potential bull trap here
0 · Reply
justiceforb_85
justiceforb_85 Nov. 6 at 3:07 AM
$LRMR when is the next data release for nomlabofusp specifically on clinical outcomes?
1 · Reply
Primitivetablemaker
Primitivetablemaker Nov. 6 at 3:02 AM
0 · Reply
Dani_G_German
Dani_G_German Nov. 5 at 5:33 PM
$LRMR they used up a lot of their cash in a short span
1 · Reply
Primitivetablemaker
Primitivetablemaker Nov. 5 at 4:36 PM
0 · Reply
i_am_the_walrus_67
i_am_the_walrus_67 Nov. 5 at 3:36 PM
$LRMR The clarity on the AEs was helpful. The percent anaphylaxis starting drug was 10% (although that number could vary with a larger sample size). The bigger news is a catalyst on the OL status and regulatory pathway update in Q1 2026. This will be the next price inflection point. Will likely linger between $3-$5 until then
1 · Reply
Latest News on LRMR
Larimar Therapeutics, Inc. - Special Call

Sep 29, 2025, 2:47 PM EDT - 2 months ago

Larimar Therapeutics, Inc. - Special Call


What's Going On With Larimar Therapeutics Stock On Tuesday?

Dec 17, 2024, 1:39 PM EST - 1 year ago

What's Going On With Larimar Therapeutics Stock On Tuesday?


Why Is Larimar Therapeutics Stock Trading Lower On Monday?

Dec 16, 2024, 12:17 PM EST - 1 year ago

Why Is Larimar Therapeutics Stock Trading Lower On Monday?


2 Potentially High-Reward Growth Stocks to Buy Right Now

May 29, 2024, 8:45 AM EDT - 1 year ago

2 Potentially High-Reward Growth Stocks to Buy Right Now

RNA


Larimar: Friedreich's Ataxia Drug With Significant Potential

Aug 2, 2023, 6:02 AM EDT - 2 years ago

Larimar: Friedreich's Ataxia Drug With Significant Potential


Larimar Therapeutics Set to Join Russell 3000® Index

Jun 21, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Set to Join Russell 3000® Index


Quantumup
Quantumup Dec. 1 at 1:03 PM
Cantor reitd $LXEO OW/$19 after survey $LRMR $BIIB Cantor Overall sentiment was very positive on LXEO, with investors expressing that the value of FA cardiomyopathy (AAVrh10- based gene therapy, LX2006) alone is undervalued (although consensus is that LXEO has a good case to support a broad FA label). Beyond this, there is some excitement around PKP2-ACM, especially as LXEO could differentiate on safety, and it represents a significant market opportunity. That said, to an extent, we still think it is under the radar and not all investors we we have spoken with appreciate the level of data LXEO has generated to date and what will be coming in January. Thus, upcoming PKP2-ACM data could put LXEO on more investor radars. Some investors are still questioning the regulatory path for gene therapy overall, and we'd highlight it's critical to understand key differences between companies and approaches. In particular, we emphasize LXEO has established its pivotal plans prior to starting this study.
0 · Reply
GoLoco511
GoLoco511 Nov. 21 at 7:42 PM
$LRMR got into this play as a fun lotto after seeing massive option volume. I believe it was a 2.5c/5c debit spread that expires today. OI still remains, there had been times that the 2.5c was quite profitable but OI never changed. Wondering if we see a big roll, or maybe it was a hedge. It’s safely ITM so it’s not expiring worthless, but I do believe it’s a bit under the breakeven from when it was opened. Have been accumulating some commons though (still don’t know shit about the company) and sold my 2.5c. Going to reenter some longer dated calls though
0 · Reply
XRaYGuru
XRaYGuru Nov. 14 at 2:52 AM
$LRMR why this is 15% in after hours?
0 · Reply
dixiebull
dixiebull Nov. 8 at 10:55 AM
$RCAT nice move from 7.75 to 9.47, see if 9.15 can hold for a move to 10 $ONDS strong Friday from 4.83 to 6.89. If 6.25 can hold this can continue to 7 and 7.50 $LRMR gets a $16.71 price target from analysts. I want 3.15 to hold on a dip to break 3.50 for 4 and 4.25 $MTC almost got 3.50 and holding 2.50 now, risky stock but if 2.50 holds it can go back to 3 and 3.50 if they decide to pump it $AREC not a fast mover but went from 3.31 to 4.16. See if 4 can hold for a move to 4.50, maybe 4.85/5 The first week of Nov was awful so we will see how this week goes. Decent earnings coming this week. We will find something.
0 · Reply
Ab3000
Ab3000 Nov. 6 at 6:49 PM
$LRMR potential bull trap here
0 · Reply
justiceforb_85
justiceforb_85 Nov. 6 at 3:07 AM
$LRMR when is the next data release for nomlabofusp specifically on clinical outcomes?
1 · Reply
Primitivetablemaker
Primitivetablemaker Nov. 6 at 3:02 AM
0 · Reply
Dani_G_German
Dani_G_German Nov. 5 at 5:33 PM
$LRMR they used up a lot of their cash in a short span
1 · Reply
Primitivetablemaker
Primitivetablemaker Nov. 5 at 4:36 PM
0 · Reply
i_am_the_walrus_67
i_am_the_walrus_67 Nov. 5 at 3:36 PM
$LRMR The clarity on the AEs was helpful. The percent anaphylaxis starting drug was 10% (although that number could vary with a larger sample size). The bigger news is a catalyst on the OL status and regulatory pathway update in Q1 2026. This will be the next price inflection point. Will likely linger between $3-$5 until then
1 · Reply
kenny91655
kenny91655 Nov. 5 at 2:59 PM
$LRMR Buying
0 · Reply
borasja
borasja Nov. 4 at 4:05 PM
$LRMR Market Positioning: If approved, nomlabofusp could become the first frataxin-replacement therapy, complementing Skyclarys (Biogen/Reata), which works via antioxidant pathways.- Biogen’s acquisition of Reata signals strong market interest in FA therapies, possibly setting the stage for future M&A involving Larimar.
0 · Reply
BiotechStockFundManager
BiotechStockFundManager Nov. 4 at 2:41 PM
$LRMR I am adding at this level.
1 · Reply
Mjh2289
Mjh2289 Nov. 2 at 4:50 PM
$LRMR does anyone know if the data presented so far included patients with skyclarys use? i believe the answer is yes and in that case im not sure how they are able to determine true impact of nomla?
1 · Reply
Zobzork
Zobzork Nov. 1 at 5:21 PM
$LRMR looks like a nice place to buy here
1 · Reply
mimiwor
mimiwor Oct. 29 at 10:36 AM
$LRMR 13 P/E.. adding adding adding...this will be my second largest swing after $CODI this year...
1 · Reply
TheGreedyGrinch
TheGreedyGrinch Oct. 27 at 4:38 PM
1 · Reply
TexasTrader2023
TexasTrader2023 Oct. 27 at 4:37 PM
$AKBA this question is for everyone , while I do not like to cross reference other tickers. I wanted to know if anyone here is invested in $LRMR ? If not , what other ticker would you consider? I scan all the time myself with certain criteria but just wanted to ask. TIA
1 · Reply
agamemnus
agamemnus Oct. 25 at 12:15 AM
$LRMR this will start going above $5 and above $6 in the next few months imo.
0 · Reply
Chartist0_0
Chartist0_0 Oct. 24 at 10:43 PM
$LRMR forming a bull flag. No break out yet. Volume has been declining. Next week might be a pullback week. I think we want to be buyers on weakness.
0 · Reply
BioResearcher
BioResearcher Oct. 24 at 7:18 PM
$LRMR So, if approved, this will be a block-buster drug with revenue far exceed $ one billion !
2 · Reply
BioResearcher
BioResearcher Oct. 24 at 7:16 PM
$LRMR LRMR 's drug will likely be priced from $ 800K - one mil per year. IMHO. Look at other rare disease like DMD drugs, it costs about $700 - one mil a year. but FA is more rare than DMD, and LRMR's drug is treating the root of FA, most DMD drugs just treat some symptoms of DMD. In US, there are about 5,000 FA patients while DMD has about 15,000 patients. The price of the drug is proportional to the rare-ness of the disease. An example: this is recently approved drug for DMD:
0 · Reply